# SACTION01 (NCT05319574)

> SBRT Followed by Neoadjuvant Immunochemotherapy in Resectable Stage II to III Non-small Cell Lung Cancer

No report yet. It can be ordered.

- Drugs tested: tislelizumab plus platinum-based chemotherapy plus stereotactic body radiotherapy
- Indication: resectable stage II–III EGFR wild-type non-small-cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05319574
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Sun Yat-sen University
- Conditions: Carcinoma, Non-Small-Cell Lung
- Interventions: SBRT; Tislelizumab
- Enrollment: 46
- Primary outcome: Major Pathological Response (MPR)

## Indexed commentary on SACTION01 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=saction01-nct05319574